Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688076 · ClinicalTrials.gov registry record · Phase 4
Treatment of Forehead/Glabellar Rhytide Complex With Botulinum Toxin A Injection
A Phase 4 study of Forehead Rhytid Complex and Glabellar Rhytid Complex, sponsored by Northwestern University.
- Active
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01688076: Active Phase 4 study of Forehead Rhytid Complex and Glabellar Rhytid Complex, sponsored by Northwestern University.
NCT01688076 is a Phase 4 study of Forehead Rhytid Complex and Glabellar Rhytid Complex that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01688076, a Phase 4 study of Forehead Rhytid Complex and Glabellar Rhytid Complex, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This cross-over design study will evaluate the onset of action, efficacy, and duration of botulinum toxin A treatment on forehead/glabellar rhytid complexes with and without subsequent muscle contraction.
Primary Outcome
A single dermatologist will rate each photograph of the subject's forehead/glabellar rhytid complex at baseline, 1 day, 2 days, 3 days, 4 days, 7 days, 2 weeks, 7 months and 1 day, 7 months and 2 days, 7 months and 3 days, 7 months and 4 days, 7 months and 7 days, and 7 months and 2 weeks. A glabellar wrinkle score and a forehead wrinkle score will be assigned to each photograph. The dermatologist will not know at what point in time the photographs were taken.
Conditions Studied
Interventions
- PROCEDURE Botulinum Toxin A
Study Locations (1)
Illinois
- Northwestern University Feinberg School of Medicine, Department of Dermatology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-01 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
What the registry record for NCT01688076 still lists
NCT01688076 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Forehead Rhytid Complex appearing as the primary indexed condition, and to 1 intervention - of which Botulinum Toxin A is the first listed.
NCT01688076 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01688076 about?
NCT01688076 is a clinical study titled "Treatment of Forehead/Glabellar Rhytide Complex With Botulinum Toxin A Injection". This cross-over design study will evaluate the onset of action, efficacy, and duration of botulinum toxin A treatment on forehead/glabellar rhytid complexes with and without subsequent muscle contraction.
What is the current status of trial NCT01688076?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2012-01. Estimated completion is 2025-12.
What conditions does trial NCT01688076 study?
This clinical trial studies the following conditions: Forehead Rhytid Complex, Glabellar Rhytid Complex.
What interventions are being tested in trial NCT01688076?
The interventions under investigation include: Botulinum Toxin A (PROCEDURE).
Who is sponsoring clinical trial NCT01688076?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01688076 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01688076's enrollment target sits among peer trials
25 1669th of 2000 higher than 303 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia